| Name | Title | Contact Details |
|---|---|---|
John Zubiena |
Interim Chief of Human Resources | Profile |
Tecan Group Ltd. is a Swiss company providing laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics for pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories.
Haynes Ambulance Of Alabama is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Protab Laboratories is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a non-profit business league, we`re funded by the healthcare industry to make the system work better for everyone. We do this work because we envision a future where providers can focus on delivering care. Health plans can focus on serving their customers. Purchasers can feel confident they`re getting the most value for their money. And where patients can ultimately get the best possible care at an affordable price. What brings us together at IHA is our passion to create a system where patients always receive the best possible care. We leave our egos at the door. We embrace the tough conversations. And we never lose sight of driving results. United by our values of Collaboration, Candor and Impact, our dedicated team works every day in support of high-quality, efficient care for all Californians. Our 40-member board of directors includes leaders from health plans, physician organizations, hospitals, health systems, purchasers, consumer groups, universities, and pharmaceutical and technology companies.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.